These findings suggest that TGF-β activates NF-κB via the p38 MAPK pathway in lung cancer cells and that (1), (5), (8), and (9) effectively suppress TGF-β-induced IL-6 secretion through inhibition of the p38-NF-κB signaling cascade. This evidence concerns the gene NFKB1 and lung carcinoma.